What Is Foundayo (Orforglipron)? Lilly's FDA-Approved Oral GLP-1 Weight Loss Pill

Foundayo (orforglipron) is an FDA-approved oral GLP-1 receptor agonist developed by Eli Lilly. The FDA approved Foundayo on April 1, 2026, making it the second oral GLP-1 pill approved for obesity (after the Wegovy pill in December 2025) and the first non-peptide oral GLP-1 agonist ever approved. Unlike every other GLP-1 drug on the market — which are injectable peptides — orforglipron is a small molecule that can be taken as a once-daily pill with no food or water restrictions.

In the Phase 3 ATTAIN-1 trial, Foundayo produced 12.4% body weight loss at 72 weeks. In a head-to-head diabetes trial (ACHIEVE-3), it outperformed oral semaglutide on both HbA1c reduction and weight loss. The FDA fast-tracked Foundayo under its Commissioner's National Priority Voucher program — the approval took just 50 days after filing, the fastest for a new molecular entity since 2002.

Foundayo is available at pharmacies and through LillyDirect with free home delivery, starting at $149/month for self-pay patients. It is part of Eli Lilly's broader weight loss portfolio alongside tirzepatide (Mounjaro/Zepbound) and retatrutide.

How Orforglipron Works

A Non-Peptide GLP-1 Agonist

Every currently approved GLP-1 drug — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — is a peptide. Peptides are chains of amino acids that get destroyed by stomach acid and digestive enzymes, which is why they require injection.

Orforglipron solves this by being a non-peptide small molecule. It is chemically synthesized (not biologically derived) and is stable in the gastrointestinal tract. This means:

• No injection needed — taken as a once-daily oral pill
• No fasting required — unlike oral semaglutide (Rybelsus), which requires 30 minutes of fasting with only a sip of water
• No food or water restrictions — can be taken at any time of day with or without meals

Biased Agonism

According to Lilly Medical, orforglipron binds to the same GLP-1 receptor as native GLP-1 but exhibits biased agonism — it favors G-protein signaling (specifically cAMP accumulation, which drives the therapeutic effects) over beta-arrestin recruitment (which leads to receptor downregulation).

In practical terms: orforglipron activates the receptor's beneficial pathways (appetite suppression, insulin secretion, slowed gastric emptying) while potentially causing less receptor desensitization over time. This is a partial agonist — it does not fully activate the receptor to the same extent as injectable GLP-1 peptides.

What It Does in the Body

Like all GLP-1 receptor agonists, orforglipron:

• Reduces appetite by acting on GLP-1 receptors in the hypothalamus
• Stimulates insulin secretion in response to food (glucose-dependent)
• Suppresses glucagon after meals, preventing excess liver glucose output
• Slows gastric emptying, prolonging fullness after eating

The same receptor, the same downstream effects — just delivered in a pill instead of a needle.

Clinical Trial Data

ATTAIN-1 (Phase 3 — Obesity Without Diabetes)

The ATTAIN-1 trial enrolled 1,686 adults with obesity or overweight (BMI 27+ with comorbidities) without diabetes. Results at 72 weeks:

All three orforglipron doses met the primary endpoint of superior weight loss vs placebo. The 36 mg dose also showed significant improvements in cardiometabolic risk factors including waist circumference, blood pressure, and fasting glucose. Among 1,127 participants with prediabetes at baseline, orforglipron significantly reduced progression to type 2 diabetes.

ACHIEVE-3 (Phase 3 — Head-to-Head vs Oral Semaglutide in T2D)

The ACHIEVE-3 trial, published in The Lancet in February 2026, was the first head-to-head trial comparing two oral GLP-1 therapies. In 1,698 adults with type 2 diabetes on metformin:

Orforglipron 36 mg produced 73.6% greater relative weight loss than oral semaglutide 14 mg. It also outperformed on every primary and key secondary endpoint.

Important caveat: the oral semaglutide doses used (7 mg and 14 mg) are the diabetes-indication doses. Novo Nordisk's obesity-indication oral semaglutide (the Wegovy pill, approved December 2025) goes up to 25 mg, which would likely narrow the gap.

Phase 2 (Obesity)

An earlier Phase 2 trial in 272 adults without diabetes showed orforglipron 36 mg achieved -9.6% weight loss at 36 weeks — the data that drove Phase 3 development. Results were published in NEJM.

Foundayo Dosing

Foundayo is taken once daily as an oral tablet. The approved dosing uses a titration schedule across six dose strengths:

No food or water restrictions at any dose. Can be taken at any time of day.

Foundayo Side Effects

The side effect profile is consistent with the GLP-1 drug class, though GI side effects may be somewhat more pronounced than with oral semaglutide.

From ATTAIN-1

Most GI side effects were mild to moderate and concentrated during the titration period. In the ACHIEVE-3 head-to-head trial, nausea and vomiting were more common with orforglipron than with oral semaglutide at the doses tested.

How Orforglipron Compares to Other Drugs

Orforglipron trades maximum weight loss for maximum convenience. It produces less weight loss than injectable options (roughly half of what retatrutide achieves), but eliminates the injection barrier entirely — no needles, no refrigeration, no injection site reactions.

Orforglipron vs Retatrutide

Both drugs are made by Eli Lilly and will likely coexist in Lilly's product portfolio. They serve fundamentally different roles:

• Orforglipron: An oral pill for people who want convenience and are needle-averse. Best suited as a first-line option in primary care — easy to prescribe, easy to take, moderate weight loss.
• Retatrutide: An injectable triple agonist for people who want maximum weight loss. Best suited for more severe obesity or people who have plateaued on other drugs — 28.7% weight loss from a single molecule.

Lilly's strategy appears to be offering a full spectrum: orforglipron for accessibility, tirzepatide for established efficacy, and retatrutide for maximum weight loss.

For a detailed comparison, see our retatrutide vs orforglipron article.

FDA Approval and Pricing

The FDA approved Foundayo (orforglipron) on April 1, 2026, for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. It was approved under the FDA's Commissioner's National Priority Voucher program — the fastest new molecular entity approval since 2002, issued just 50 days after filing.

Foundayo became available at pharmacies and through LillyDirect with free home delivery starting April 6, 2026.

Foundayo Cost

*For the 14.5 mg and 17.2 mg doses, the $299 price requires refill within 45 days. Standard pricing of $349/month applies if refills are delayed.

Patients with commercial insurance can use the Foundayo Savings Card for copays as low as $25/month. Medicare Part D coverage may average around $50/month when available (expected July 2026).

Frequently Asked Questions

Sources

1. Wharton S, et al. "Orforglipron in adults with obesity." New England Journal of Medicine. 2025. Lilly Press Release
2. Rosenstock J, et al. "Orforglipron vs oral semaglutide in type 2 diabetes (ACHIEVE-3)." The Lancet. 2026. Lilly Press Release
3. Sloop KW, et al. "The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron." PubMed
4. Kansakar U, et al. "Orforglipron: A Comprehensive Review." Int J Mol Sci. 2026;27(3):1409. PMC
5. Eli Lilly. "Mechanism of action of orforglipron." Lilly Medical
6. Park A. "FDA Approves Eli Lilly's Obesity Pill, Foundayo." Time. April 2, 2026. Time
7. Lupkin S. "Eli Lilly obesity pill Foundayo gets the FDA green light." NPR. April 1, 2026. NPR
8. Drugs.com. "How much does Foundayo cost?" April 2026. Drugs.com

Medical Disclaimer

The information on this page is for educational purposes only and is not medical advice. Foundayo (orforglipron) is an FDA-approved prescription medication. Always consult a qualified healthcare provider before making decisions about medications or treatments. Do not use this information to self-diagnose, self-treat, or make changes to prescribed therapy.